Collegeville, PA, United States of America

Brian W Budzik



Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • King of Prussia, PA (US) (2013)
  • Collegeville, PA (US) (2011 - 2022)

Company Filing History:


Years Active: 2011-2022

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Brian W Budzik: Innovator in Pharmaceutical Chemistry

Introduction

Brian W Budzik is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of TRPV4 antagonists. With a total of 9 patents to his name, Budzik's work has had a considerable impact on medical research and drug development.

Latest Patents

Among his latest patents, Budzik has focused on TRPV4 antagonists. His inventions relate to pyrrolidine sulfonamide analogs, which are pharmaceutical compositions that have shown promise in their use as TRPV4 antagonists. This innovative approach has the potential to lead to new treatments for various medical conditions.

Career Highlights

Throughout his career, Brian W Budzik has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research.

Collaborations

Budzik has collaborated with esteemed colleagues in his field, including Jian Jin and David G Cooper. These partnerships have fostered an environment of innovation and have led to the successful development of his patented inventions.

Conclusion

Brian W Budzik stands out as a significant figure in pharmaceutical innovation, with a focus on TRPV4 antagonists and a strong background in the industry. His contributions continue to influence the landscape of medical research and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…